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Abstract. More men die with prostate cancer (PCa) than from
it. However, once PCa is no longer organ-confined, it is
associated with significant mortality. Epithelial-to-mesenchymal
transition (EMT) is one mechanism facilitating progression in
cancer. Our studies of transglutaminase-4 (TGase-4), a member
of the TGase family, expressed in the prostate gland, have
implicated it in the regulation of the invasive properties of PCa.
The present study investigated the role of TGase-4 on EMT of
PCa cells. Materials and Methods: A panel of PCa cell lines:
CA-HPV-10, PZ-HPV-7, PC-3 and DU-145 were used. An anti-
TGase-4 transgene was constructed to eliminate the expression
of TGase-4 in CA-HPV-10 (positive for TGase-4). An expression
construct for human TGase-4 was used to transfect PCa cells
negative for TGase-4. The pattern of E-cadherin, N-cadherin
and vimentin in these cells were evaluated using
immunofluorescent staining. Cell motility was assessed using
scratch wounding and ekectric cell-substrate impedance sensing
(ECIS) assays. Results: Treatment of PZ-HPV-7 and CA-HPV-
10 cells with rhTGase-4 resulted in a significant increase in cell
migration (1,407.9 Ω±6.4 Ω vs. 1,691.2 Ω±8.3 Ω in non-treated
and rhTGase-4 treated cells, respectively, p<0.01). Cells
strongly expressing E-cadherin showed substantial changes of
E-cadherin staining in that, after treatment with TGase-4, the
intercellular staining of E-cadherin was diminished.
Concomitantly, there was acquisition of N-cadherin in TGase-
4-treated cells. Elimination of TGase-4 from CA-HPV-10 cells
significantly decreased cell motility (128.1 Ω±107.4 Ω vs. 31.7
Ω±26.2 Ω, in CA-HPV-10 control and CA-HPV-10/TGase-4
knockout cells). Knocking- out TGase-4 from CA-HPV-10 cells
also resulted in substantial loss of N-cadherin in the cells.
Conclusion: TGase-4 resulted in loss of E-cadherin/acquisition
of N-cadherin and cell migration indicating it is a keen
regulator of EMT in prostate epithelia-derived cancer cells. In
concert with its other properties involved in disease
progression, the present observations suggest TGase-4 as a
prospective marker of disease progression.
Prostate transglutaminase, also known as transglutaminase-
4 (TGase-4) belongs to the transglutaminases (EC 2.3.2.13
[TGases]) family of proteins (1, 2) and is expressed in a
pattern different from other members of the TGase family.
TGase-4 expression is restricted to the prostate gland (3, 4).
The biological and pathological roles for TGase-4 are not at
all clear. In prostate cancer (PCa), TGase-4 expression
remains controversial, with reports showing a possible
differential expression in normal prostate epithelial cells and
PCa cells (5, 6). However, these early studies were limited,
particularly in the methodological approach utilized. The full
implications of TGase-4 in PCa require further investigation.
The rat homologue of TGase-4, rat prostate TGase (or
DP1) has been suggested to be responsible for the cross-
linking during the copulatory plug formation and may be
involved to some degree in sperm cell motility and
immunogenicity (7, 8). There has been some recent interest
in the biological role of TGase-4 in PCa cells. TGase-4 was
found to be able to stimulate the invasiveness of PCa cells
and assist tumor-endothelial interactions (9, 10). The
terminology of epithelial– mesenchymal transition describes
the events that convert adherent epithelial cells into
individual migratory cells that can invade the extracellular
matrix and has been collectively referred to as epithelial-to-
mesenchymal transition (EMT) (11, 12). At a biomedical and
molecular level, EMT is characterized by such changes as
the cadherin switch, loss of cytokeratin, increased expression
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of vimentin and collagen, spindle-like morphology and gain
of migration. EMT is widely involved in embryonic
development and pathological conditions, and occurs during
the progression of cancer (11). Mesenchymal-like cancer
cells are associated with an aggressive phenotype (13).
Our recent studies and observations of cell morphology
when TGase-4 expression was manipulated in PCa
stimulated the present study in which we investigate the
impact of TGase-4 on EMT in PCa cells.
Materials and Methods
Materials. Human PCa cell lines, PC-3, DU-145, CA-HPV-10, and
PZ-HPV-7 were obtained from the ATCC (Manassas, VI, USA).
Rabbit anti-human TGase-4 antibodies were obtained from ABCAM
(Cambridge, UK), rat monoclonal anti-human TGase-4 was from
Abnova (Taipei, Taiwan). Monoclonal anti-human E-cadherin and
anti-vimentin were from Sigma-Aldrich (Little Chartfont, UK).
Polyclonal anti-human N-cadherin, anti-CK19, monoclonal anti-
actin and anti-GAPDH were from Santa Cruz Biotechnologies Inc.
(Santa Cruz, CA, USA). Full length recombinant human TGase-4
was from Abnova. All other chemicals were from Sigma-Aldrich,
unless stated otherwise.
Creation of sublines of PCa cells in which TGase-4 transcripts were
knocked down by way of ribozyme transgenes and by over-
expressing TGase-4 in the cells. We created a set of sublines from
prostate cancer cells in which the expression of TGase-4 transcript
was knocked down by way of ribozyme transgenes, as recently
reported (9). Briefly, using anti-human TGase4 ribozyme transgenes
created recently, we established the following new sublines: TGase-
4 knock-down cells (designated here as CA-HPV-10ΔTGase4 in this
manuscript), plasmid only control cells (CA-HPV-10pEF6), and the
wild type, CA-HPV-10WT. Similarly, using a human TGase-4
expression construct, we established stably transfected sublines: PC-
3pEF/His and PC-3TGase4exp, for control transfection and TGase-4
expression, respectively.
RNA preparation, RT-PCR and quantitative real-time PCR. RNA
from cells was extracted using the Tri-reagent solution (Sigma-
Aldrich) and concentration quantified using a spectrophotometer
(Wolf Laboratories, York, UK). PCR was performed using sets of
primers (Table I). β-Actin was amplified and used as a house
keeping control. PCR products were then separated on a 0.8%
agarose gel, visualised under UV light, photographed using a
Unisavetm camera (Wolf Laboratories, York, England, UK) and
documented with Photoshop software. Real time PCR was
conducted as we previously reported (14), using specific primers as
shown in Table I.
In vitro cell growth assay. This was based on a previously reported
method (14). In brief, cells were plated into 96-well plated at 2,000
cells/well followed by a period of incubation. Cells were fixed in
10% formaldehyde on the day of plating and daily for the
subsequent 5 days and 0.5% crystal violet (w/v) was used to stain
cells. Following washing, the stained crystal violet was dissolved
with 10% (v/v) acetic acid and the absorbance was determined at a
wavelength of 540 nm using an ELx800 spectrophotometer.
Absorbance represents the cell number.
Electric cell-substrate impedance sensing (ECIS)-based cell
adhesion assay. Two models of ECIS instrument were used: ECIS
9600 (for screening) and ECIS1600R (for modelling). In both
systems, 8W10E arrays were used (Applied Biophysics Inc, Troy,
NY, USA) (10, 15). 300,000 respective were added to each wells.
Electric changes were continuously monitored for up to 24 hrs. In
the 9600 system, the monitoring was at fixed 30Hz. In the 1600R
system, two conditions were recorded: 400Hz, 4,000Hz, 40,000Hz
for screening the nature of endothelial changes and 4,000Hz fixed
frequency for cell modelling.
Immunofluorescence staining in cells and tissues. Cells were seeded
in 16-well chamber slides and allowed to adhere overnight. After
fixation with 5% formaldehyde, cells were treated with 0.2% Triton
x100 for 5 min, before being incubated for 20 min in a 10% horse
serum blocking solution. Cells were then probed with an appropriate
primary antibody. Following extensive washings, sections were
incubated for 30 min in the secondary FITC- and TRITC conjugated
in the presence of Hoescht 33258 at 10 μg/ml (Sigma). Following
extensive washings, the slides were mounted using Flurosave™
mounting media (Calbiochem, Nottingham, UK) and allowed to
harden overnight at 4˚C, before being examined. Slides were
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Table I. Primer and oligo sequences for PCR, ribozyme and amplification of full coding sequence of  prostate transglutaminase (TGase-4).
                                                                                  Sense (5’-3’)                                                                            Anti-Sense (5’-3’)
TGase-4 expression                                            atgatggatgcatcaaaaga                                                            ctacttggtgatgagaacaatcttctga
TGase-4 ribozyme1                                           atgatggatgcatcaaaagag                                                                  ctacttggtgatgagaacaa
TGase-4 ribozyme1                     ctgcagtttggaactcccatgtgtggtgactgatgagtccgtgagga                           actagttgaatcaggacaacgccgtttttcgtcctcacgga
TGase-4 ribozyme2                         ctgcagttcagttggtggtggtagctgatgagtccgtgagga                                    actagtccagcccctacaatttcgtcctcacggga
TGase-4 (position 62)                                        atggatgcatcaaaagagc                                                                    aggtgaaacacctgtcctc
                                                                                                                                                       actgaacctgaccgtacaaggtgaaacacctgtcctc, for Q-PCR))
TGase-4 (position 1957)                                    ataaaatgcaccccaataaa                                                                  ctacttggtgatgagaacaatc
                                                                                                                                                      (actgaacctgaccgtacatacttggtgatgagaacaatc, for Q-PCR)
GAPDH                                                               agcttgtcatcaatggaaat                                                                     cttcaccaccttcttgatgt
GAPDH for Q-PCR                                            ctgagtacgtcgtggagtc                                                     actgaacctgaccgtacacagagatgatgacccttttg
β-actin                                                                   atgatatcgccgcgctcg                                                                      cgctcgtgtaggatcttca
examined using an Olympus fluorescence microscope and
photographed using a Hamamatsu digital camera. The images were
documented using the Cellysis software (Olympus). 
Statistical analysis was carried out using Minitab. For normality
test: Anderson-Darling test and for statistical difference Student’s t-
test.
Results
Expression of TGase-4 in PCa cells resulted in significant
increase in cellular motility. Sublines from PC-3 (TGase-4-
negative, Figure 1) and CA-HPV-10 (strongly positive for
TGase-4) cells were created. PC-3 cells over-expressed
TGase-4, as shown by immunocytochemical analysis and
analysis of gene transcripts (Figure 1). In CA-HPV-10 cells
and using anti-TGase-4 ribozyme transgenes, we knocked-
down the expression of TGase-4 (Figure 1B and C). Using
these new sublines, we compared the difference in cellular
motility from their parent lines. 
As shown in Figure 2A, and as previously reported, over-
expression of TGase-4 in PC-3 cells resulted in an increase
in cell migration in comparison to control transfected cells.
In contrast, CA-HPV-10 cells strongly positive for TGase-4
and with a limited degree of motility, migrated faster on loss
of TGase-4 by way of ribozymes.
In order to evaluate the effects of exogenous TGase-4 on
PCa cells, we used recombinant human (rh) TGase-4 directly
on a panel of PCa cells. Shown in Figure 2 (B-D), in both
PZ-HPV-7 and DU-145 cells which are negative for TGase-
4 as shown in previous study (9), rhTGase-4 resulted in an
increase in cell migration. 
Over-expression of TGase-4 in PCa cells resulted in
reduction of E-cadherin in the cells. Here, the effect of
whether treating the PZ-HPV-7 cells, that are positive for E-
cadherin and largely negative for N-cadherin, would cause
any changes in the cell adhesion molecules were evaluated.
DU-145 cells, weakly positive for E-cadherin, lost the
staining of the cell adhesion molecule after treatment with
rhTGase-4 (Figure 3). Shown in Figure 4, rhTGase-4
treatment rendered cells with far less E-cadherin staining in
comparison with non-treated cells (right panel). Interestingly
and concomitantly, there appears to be an increase in N-
cadherin staining in the cells (left panel, Figure 4).
Knocking-down TGase-4 in CA-HPV-10 cells and the
resulting changes in N-cadherin and vimentin. To further
evaluate the relationship between TGase-4 and EMT, we
used the CA-HPV-10 cell model created in the study (Figure
1) in which we knocked-down the expression of TGase-4.
Shown in Figure 4, after loss of TGase-4, there were
increased staining for N-cadherin and vimentin, markers for
mesenchymal cells, in the cytosol of the cells. The same was
seen with PZ-HPV-7 cells.
Discussion
Prostate transglutaminase, TGase-4, is a protein uniquely
expressed in the prostate gland, but with little biological
functions assigned to the molecule. In the present study, we
have provided evidence for the first time that TGase-4 is a
protein important to the EMT process in PCa cells. 
TGase-4 has recently been shown to be able to regulate the
invasiveness and migratory property of PCa cells (9, 10). In
these previous studies, it has been shown that a gain of
TGase-4 in PCa cells resulted in an increase in the migration
speed and invasiveness of PCa cells. Vice versa, loss of
TGase-4 correlates with the decrease of motility of the cells,
an observation further made within the present study. In
concert with changes of cell morphology following the
change of TGase-4 in the cells, are characteristics of the
hallmark of EMT in cells. The present study has provided
much needed support to confirm the occurrence of EMT in
the PCa cells, after expression of TGase-4. Our data has
shown that both over-expressing TGase-4 in PCa cells and
treatment of PCa cells with exogenous TGase-4 resulted in a
loss of E-cadherin in the cells, and to some degree an increase
in N-cadherin, a cadherin switch. Thus, it is clear that high
levels of TGase-4 are associated with the biochemical and
molecular markers indicative of EMT in the cells. 
Agents/molecules regulating EMT in PCa cells are rather
hard to come by. Zhu and Kyprianou (16) have shown that
androgen is able to induce EMT in PCa cells. The same has
been reported for IGF-I and by induction of FGFR1 (17, 18).
It is very interesting to note, however, that some of the
prostate-specific proteins, namely kallikrein 4 and kallikrein-
3 (PSA) are also regulators of EMT in PCa cells (19). Thus,
TGase-4 may well act as a powerful EMT-inducer in the
host, similar to that observed with PSA in the induction of
EMT and tumour progression in PCa. 
Although the present study is the first to report the effect
of a prostate-specific TGase on the EMT of PCa cells, it has
been recently reported that TGase, namely TGase-2 is able to
induce EMT in cancer cells (20, 21). In these studies, and
similar to the findings reported here, TGase-2 has been found
to induce loss of E-cadherin in mammary epithelial cells and
ovarian cancer cells. It is also interesting to note that TGase-
2 alone is sufficient to induce EMT, again similar to TGase-
4. Thus, it appears that TGases, at least TGase-2 and TGase-
4, are commonly involved in the regulation of EMT.
A number of transcription factors including snail, twist,
ZEB1 and slug are known to induce EMT in PCa cells, by
regulating the expression of the cadherins (22-24). It will be
useful to investigate the potential effect of TGase-4 on these
factors in PCa cells. The therapeutic value of targeting EMT-
related cellular and molecular events has been proposed in
recent years. Although, TGase-4 in the present and previous
studies have been demonstrated to be a factor associated with
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Figure 1. Creation of prostate cancer sublines with differential expression of TGase-4. A: over-expression of TGase-4 in PC-3 cells after transfection
as shown by immunocytochemical staining of control vs. transfected cells. B and C: Qualitative (B) and quantitative (C) analysis of TGase-4
transcripts in PC-3 and CA-HPV-10 cells, after transfection. 
aggressiveness of PCa cells, the clinical implication of
TGase-4 in patients with PCa is yet to be fully established.
In this regard, preliminary comparative immunohistochemical
study of normal and malignant human prostate tissues have
shown an increase in TGase-4 in association with the
Gleason score (25).
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Figure 2. A: Expression of TGase-4 and the pace of cell migration as determined by ECIS. Shown are PC-3 cells transfected with a control plasmid
and those with TGase-4 expression construct. Cells over-expressing TGase-4 had a marked increase in migration. B, C and D: The effects of rhTGase-
4 on the migration of prostate cancer cells. B: traces of the cell migration after wounding (time-0) showing the normalised impedance of the cells. C
and D: Cellular motility after cells being treated by rhTGase-4 as in A. Shown are resistance following Rb modelling. *p<0.05 vs. no treatment control.
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Figure 3. Treatment of prostate cancer cells with rhTGase-4 resulted in N-cadherin/E-cadherin shift. Left and middle panel are PZ-HPV-7 cells and
right panel are DU-145 cells. Top panels are control and bottom panels are cells treated with rhTGase-4. Arrows indicate cadherin staining.
Figure 4. Knocking-down TGase-4 from CA-HPV-10 cells resulted in changes in reduction of N-cadherin from the cells (bottom). Left: N-cadherin;
right: vimentin staining. TGase-4rib: anti-TGase4 ribozyme transgene transfected cells. 
In conclusion, TGase-4, a protein enzyme unique to the
prostate gland, is associated with the invasive and migratory
properties of PCa cells. It induces biochemical and molecular
events leading to the conclusion that it is a inducer of the
EMT in PCa cells. 
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